Unraveling The Key Questions in EGFR-Driven NSCLC Treatment - Episode 5
MARIPOSA: Clinical Implications
Panelists discuss how the MARIPOSA trial demonstrated strong efficacy with amivantamab plus lazertinib that appears comparable to FLAURA2’s results with osimertinib plus chemotherapy, although cross-trial comparisons should be interpreted cautiously given differences in study populations and the need for mature overall survival data from both trials.
Video Player is loading.
Video content above is prompted by the following:
- MARIPOSA evaluated amivantamab with lazertinib. How does the progression-free survival and overall response rate data from MARIPOSA compare with the outcomes seen in FLAURA2?
